<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsFei Su, Jeffrey A. Sosman, Gideon Bollag et al.|New England Journal of Medicine|2012Cited by 1k
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG. Saturno, Caroline J. Springer, Filipa M. Lopes et al.|Annals of Oncology|2020Cited by 21